Committed to Pushing the Boundaries of Brain Health
VoxNeuro is a Software as a Medical Device (SaMD) brain health company that analyzes brain-based biomarkers to assess cognitive function. Our research and innovation is a constant, and our technology will continue to advance the way brain health is managed.
Jason is the CEO of VoxNeuro. As CEO, Jason leads the planning and execution of VoxNeuro’s short and long-term business strategies while managing its allocation of capital and entry into new markets. Jason serves VoxNeuro’s stakeholders, including its Board of Directors and investors, and leads the team in its effort to become The Brain Company.
Jason brings over 25 years of industry-relevant, executive leadership experience to VoxNeuro. His success in the life sciences and health technology sectors began with pharmaceutical leaders, Bayer and Johnson & Johnson, followed by CEO roles across specialty pharma, medical device, diagnostics and health tech companies. During his time building and leading these companies, Jason was successful in the pursuit of new markets, investment capital, revenue growth and multiple liquidity events.
John Connolly is a co-founder and Chief Science Officer of VoxNeuro. John provides scientific oversight of VoxNeuro’s application to acquired brain injuries, as well as neurological disorders and conditions. He also leads the design of projects to investigate new applications for VoxNeuro’s technology.
John received his PhD from King’s College London, and served as the Senator William McMaster Chair in the Cognitive Neuroscience of Language from 2010-2022. Currently, he co-directs the Language, Memory & Brain Lab and is Professor Emeritus at McMaster University, appointed in the Faculties of Engineering, Health Sciences, Science and Humanities. His work has been documented in over 300 peer-reviewed publications and has been supported by funding agencies across the world for almost 40 years. In addition to his work with VoxNeuro, John actively reviews research for a wide range of journals and funding agencies, is a Faculty Affiliate at the Vector Institute of Artificial Intelligence, and is a member of Brain Injury Canada’s Scientific Advisory Committee.
James is the co-founder and CBO of VoxNeuro. James leads VoxNeuro’s overall commercial strategy and ensures operations remain focused and accelerated. Whether it be employees, clients, partners, investors, or patients, James dedicates his time to serving VoxNeuro’s stakeholders and building out VoxNeuro’s ability to grow its presence and support the communities VoxNeuro serves.
Before co-founding VoxNeuro in 2017 James spent the first nine years of his career in commercial development roles across various industries including automotive, financial, media, and healthcare. Most recently James led US client development for Dentsu Aegis Network, the 3rd largest media conglomerate in the world. Leading their US client team, James led strategic initiatives to drive growth for their largest US accounts including Pfizer, Microsoft, Diageo, and Northrop Grumman. James completed his studies with a specialty in business process integration from the Hogeschool van Amsterdam and a Bachelor of Commerce from the University of Ottawa’s Telfer School of Management in 2010.
Kimberly is a co-founder and Chief Operating Officer of VoxNeuro. Kimberly works directly with the CEO and Board of Directors to develop and manage VoxNeuro’s strategic and operational plans, executing on VoxNeuro’s goals for performance and growth. Kimberly oversees business operations as a whole with focus on Legal, Finance, Communications, Clinical Operations, Human Relations, and Corporate Social Responsibility in concert with department leads.
Before founding VoxNeuro, Kimberly made her career in account management at leading creative advertising agencies including DentsuBos in Toronto and mcgarrybowen in New York. From managing clients including JCPenney in the US market, and Canon and Manulife in Canada, Kimberly developed strong skills in communications, strategy, budget and project management – keeping clients and her teams focused, on time and on budget.
Kimberly was born in Calgary and grew up primarily overseas in The Netherlands and Malaysia before returning to Canada for university and to start her career. With a world view engrained in her thinking, she’s laser focused on the global impact VoxNeuro will have on how brain health is managed.
As Vice President, Clinical & Scientific Affairs, Kyle is responsible for ensuring the highest standard of care for patients through the strategic leadership of VoxNeuro’s clinical and scientific practices. This includes the oversight of the Research & Development, Clinical Operations and Regulatory Affairs & Quality Assurance departments, with a focus on product development and expanding the medical applications of VoxNeuro’s technology.
Dr. Ruiter was awarded his Ph.D. from McMaster University’s Cognitive Science of Language Program. Dr. Ruiter received extensive training in cognitive neuroscience; specifically, with expertise in electrophysiology and the neurophysiological consequences of concussion and other traumatic brain injuries (TBIs). He has been published in numerous peer-reviewed journals for his research in brain injury and neuroimaging. Additionally, Dr. Ruiter is well-versed in regulatory affairs; in particular, medical device hardware and software regulation for both Health Canada (HC) and the FDA. In addition to his PhD, Dr. Ruiter holds a diploma in General Arts and Science from Humber College, a Honours Bachelor’s of Applied Science in Psychology with an emphasis in Business Administration from the University of Guelph, as well as a post-graduate certificate in Regulatory Affairs from Algonquin College.
Austen is responsible for supporting the AI & Technology and Clinical Operations teams at VoxNeuro, by providing software development expertise and assisting with integration and support for the IT and business ecosystems.
Before VoxNeuro, Austen worked as an application specialist, providing application support to employees across Canada and streamlining automation by developing in-house testing software.
Prior to completing a B.Cmp at Queen’s School of Computing, Austen attended the National Ski Academy in Collingwood, where he raced in various international competitions and trained at ski resorts across North America and Europe.
Andrew is responsible for ensuring high standards of care for patients through the strategic leadership of clinical personnel, compliance with regulatory bodies, and the optimization of operational practices in clinical and research contexts.
Prior to VoxNeuro, Andrew worked as a Registered Kinesiologist, prescribing exercise in clinical and general populations. He completed a BSc in Kinesiology at the University of Guelph-Humber.
Danielle manages VoxNeuro’s clinical and professional practice education, including oversight and provision of quality and client centred care with VoxNeuro’s partners. As Manager of Clinical Education, Danielle proactively assesses and determines education programming for VoxNeuro’s clinical partners, is responsible for performance evaluation of clinical staff, develops learning plans, and delivers and evaluates practice education in support of the goals and objectives of VoxNeuro.
Before working at VoxNeuro, Danielle was an OTA/PTA with a number of rehabilitation clinics around the GTA. Danielle received her OTA/PTA certificate from Humber College.
As Brand Manager, Douglas’ primary focus lies in driving marketing and communication initiatives, acting as the primary contact for advertising and public relations partners, managing internal communications, and collaborating with the Sales, Clinical & Scientific Affairs, and Product Development teams to maintain a consistent brand strategy.
Douglas graduated from the University of Guelph with a Bachelor of Commerce, earning Dean’s List honours. Before joining the VoxNeuro team in August 2021, Douglas spent seven years in account management in the advertising industry, leading business for clients across various sectors, including financial, automotive, consumer packaged goods and retail.
As the Clinical Research & Development Associate, Renada is primarily responsible for the execution of research directives put forth by the VP of Clinical & Scientific Affairs and herself, while also supporting Product Development, Clinical Operations, and Regulatory Affairs, all falling under the Clinical & Scientific Affairs department. Renada is highly involved in internal research, scientific paper writing, data analysis, and paradigm development. She liaises with both research and commercial partners, installs equipment and trains stakeholders on VoxNeuro technology, while also ensuring compliance with industry standard regulatory and quality frameworks set forth by VoxNeuro.
In 2018, Renada completed her Bachelor’s Degree in Behaviour, Cognition, and Neuroscience at the University of Windsor. She then completed a Master’s in Neuroscience and Behaviour, also at the University of Windsor. Her undergraduate thesis was psycholinguistics based, while her graduate thesis was cellular and molecular neuroscience based, examining behaviour and mechanisms in non-human neurological disease models. Aside from her studies, Renada remains heavily involved in and passionate about brain health initiatives in the community.
Dr. John F. Connolly is the Chief Science Officer and co-founder of VoxNeuro Inc. He is the former Senator William McMaster Chair in Cognitive Neuroscience, the founding director of the ARiEAL Research Centre, and co-directs the Language, Memory and Brain Lab. He is an author on over 330 articles*, chapters, and presentations, most of which involve EEG/ERP, MEG and MRI studies of cognitive health and neuropathology.
Dr. Connolly has served as a consultant for a variety of organizations including:
- Natural Science and Engineering Research Council of Canada (NSERC)
- Canadian Institutes of Health Research (CIHR)
- Canada Foundation for Innovation
- Ontario Brain Institute (OBI)
- Ontario Centres of Excellence (OCE)
- Scottish Rite Charitable Foundation (Canada & USA)
- March of Dimes Research Foundation (USA)
- National Institutes of Health (USA)
- Heart and Stroke Foundation of Canada
- The Hospital for Sick Children (Sick Kids)
- Networks of Centres of Excellence of Canada
- Autism Speaks’ High Risk – High Impact Initiatives (USA)
- Collaborative Health Research Projects (CIHR & NSERC)
Dr. Connolly has also served as a Member of the Editorial Board and subsequently Associate Editor of Clinical Neurophysiology – the flagship journal of the International Federation of Clinical Neurophysiology.
He has served as a consultant to other research and evidence-based policy groups in Australia, New Zealand, Hong Kong, Belgium, Flanders, Finland, and the United Kingdom.
Dr. Connolly is a member of the Scientific Advisory Board for Brain Injury Canada to inform an integrated and comprehensive Brain Injury Resource website. It serves to provide reliable & evidence-based information related to brain injury, and a comprehensive list of existing services for Canadians with brain injuries, their families and caregivers.
The Scientific Breakthrough in Cognitive Assessment
In 1999, Dr. Connolly was the first person in the world to demonstrate that a patient (mis)diagnosed as being in a vegetative state (now referred to as Unresponsive Wakefulness Syndrome) was actually in a locked-in state, meaning they were fully functioning cognitively but experiencing near-complete physical paralysis. After 9 months of successful cognitive rehabilitation efforts, the patient had regained complete motor control and was discharged, walking himself out of the hospital. This landmark case led to the development of EEG-based methods of assessing conscious states and mental functions in patient populations including autism, Unresponsive Wakefulness Syndrome (vegetative state), coma, and concussion. This evidence based research forms the foundation of VoxNeuro’s technology.
Legacy Patient Testimonial
“On August 29, 2010 Rohan, my husband, set out with his friends for a leisurely ride on their bicycles. At an intersection, Rohan was struck by a speeding vehicle and was thrown 30 meters.
Rohan suffered a severe brain injury and a lot of abdominal injuries. He was deemed catastrophic with no vitals on the scene. Rohan was resuscitated by some great paramedics and was rushed to Hamilton General Hospital where he underwent 11 and a half hours of surgery and was deemed vegetative. Rohan was in a coma for about 10 days.
Rohan was moved to a stepdown unit when he started waking up and was treated by a neurologist Dr. Jane Gillette, who was not in agreement to Rohan’s initial diagnosis. Dr. Jane Gillette turned to Dr. John Connolly and said to him “The ball is in your court. Please test Rohan for brain activity as I feel the diagnosis is not correct.”
Dr. Jane Gillette’s concern was correct. Dr. John Conolly proved in his testing that Rohan was terribly injured but had full brain activity – responding to different commands, music and lots more.
Dr. John Connolly followed and still follows Rohan’s progress 9 years later. The work VoxNeuro is doing is so important and vital because Doctors come to conclusions too quickly that a severe brain injury is correlated to vegetative state.
We commend the work Dr. John Connolly and his team at VoxNeuro are doing. As we see it, they are “Giving Patients a Second and Fair Chance to Life”. Today Dr. John Conolly could retire in a nice comfy home and relax but he is still out there working to help patients – this is a testimony to dedication, passion and love for what he does and has for patients. A mission that will continue to thrive through VoxNeuro.
Our best wishes to Dr. John Connolly and VoxNeuro to their endless hours of work. Not everyone has this great gift, only few are gifted and honoured with it and Dr. John Conolly – you are the greatest one. Our thanks to you for giving Rohan a great second chance at life. Rohan is far from what the diagnosis was thanks to the information your test provided his care team early in his recovery. Rohan has fully recovered Cognitively, and his physical abilities are great, working out 7 days a week. Our best wishes in all you are doing.”
Wife of Rohan Pais – former patient.
Man deemed in vegetative state wakes up speaks again (VIDEO)
CTVNews, Sean Davidson
Waking the Brain: Advances in Neuroscience (VIDEO)
Industry Partners & Support
VoxNeuro’s science is backed by over 30 years of globally funded, peer-reviewed research led by Dr. John F. Connolly. This research began at Dalhousie University, furthered at University of Montreal, and continues to break new ground at McMaster University, where VoxNeuro launched its operations in 2017. VoxNeuro works with partners at the McMaster Industry Liaison Office in the commercialization of Dr. Connolly’s research, and is a graduate of The Forge, McMaster’s start-up incubator.
VoxNeuro has received innovation support funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Obtaining NRC IRAP funding not only serves as recognition for VoxNeuro’s focus on innovation, but also served as a catalyst for the company’s growth and ability to scale, funding the development of the Cognitive Health Assessment Management Platform™.
VoxNeuro is a member of the Hamilton Chamber of Commerce. As a part of the Hamilton community, VoxNeuro is dedicated to building Hamilton’s reputation as one of Canada’s leading innovative cities in healthcare, while helping to promote and enhance business growth and activities across the City of Hamilton.
The Government of Canada’s Trade Commissioner Service selected VoxNeuro as 1 of 11 emerging growth Canadian Life Sciences companies to participate in the Canadian Technology Accelerators’ inaugural bi-coastal program led by the Consulates General of Canada in New York and San Francisco. The program, which concluded in November 2020, was dedicated to the development of high-potential, early-stage digital health start-ups into the San Francisco and New York healthcare ecosystems, priming VoxNeuro’s US market entry in 2021.